539 - Clesrovimab Binding Site Conservation on the RSV F Protein: An Evaluation of RSV Molecular Sequencing Data from 2019-2023 and GenBank Sequence Analysis

Saturday, October 19, 2024

12:25 PM – 12:30 PM US PT

Location: Halls JK - Arena 3

Co-Author(s)

AF

Arthur Fridman, PhD

Merck & Co., Inc.
Rahway, New Jersey, United States
LL

Latisha Love-Gregory, PhD

Merck & Co., Inc.
Rahway, New Jersey, United States
RR

Radha Railkar, PhD

Merck & Co., Inc.
Kenilworth, New Jersey, United States
DL

Diane Levitan, PhD

Merck & Co., Inc.
Kenilworth, New Jersey, United States
Julie Strizki, PhD

Principal Scientist
Merck & Co., Inc.
West Point, Pennsylvania, United States

Kalpit A. Vora, PhD (he/him/his)

Distinguished Scientist, Biology-Discovery, ID/Vaccines
Merck & Co., Inc.
Rayway, NJ, United States

Disclosure(s):

Arthur Fridman, PhD: Merck & Co., Inc.: employee, Stocks/Bonds (Public Company)

Latisha Love-Gregory, PhD: Merck & Co., Inc.: Employee, Stocks/Bonds (Public Company)

Radha Railkar, PhD: Merck & Co., Inc.: Employee, Stocks/Bonds (Public Company)

Diane Levitan, PhD: Merck & Co., Inc.: Employee, Stocks/Bonds (Public Company)

Julie Strizki, PhD: Merck & Co., Inc.: Employee, Stocks/Bonds (Public Company)

Kalpit A. Vora, PhD: Merck & Co., Inc.: Employee, Stocks/Bonds (Public Company)